While L1CAM inactivation has already been shown to improve the OC response to cytostatic drugs, testing to what extent this involves targeting OCSC will require ad hoc preclinical models and clinical trials specifically designed to consider the role of OCSC in tumor relapse, metastasis initiation and acquired chemoresistance. This evidence concerns the gene L1CAM and neoplasm.